Cydex Pharmaceuticals, Inc.

Silvergate Pharmaceuticals Inc.

Azurity Pharmaceuticals, Inc.

Cydex, Inc.

Gerold L Mosher

David W Miles

James D Pipkin

Scott Brauer

Douglas B Hecker

Stephen G Machatha

Daniel Joseph Cushing

Karen T Johnson

Rebecca L Wedel

Jane A Cowee

Diane O Thompson

Rupert O Zimmerer

Roger A Rajewski

Valentino J Stella

James William McGinity

Atef Gayed

Venkatramana M Rao

Atef A Gayed

Daniel J Cushing

D Pipkin; James

Pharmaceutical formulations containing acetaminophen and sulfoalkyl ether cyclodextrin are described. The formulation includes acetaminophen; and sulfoalkyl ether cyclodextrin, wherein the molar ratio of sulfoalkyl ether cyclodextrin to acetaminophen is in the range of about 0.01 to about 2. The formulations can be prepared in an injectable form for mitigating or treating fever or alleviating pain in a patient.

Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Lisinopril formulations

Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Amlodipine formulations

Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.

DPI formulation containing sulfoalkyl ether cyclodextrin

Growing community of inventors

Kansas City, MO, United States of America

Gerold L Mosher